Veracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis (Veracyte Inc)
(WorldNews Health)

(Source: Veracyte Inc) February 21, 2017 Veracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that ten Blues plans have recently issued new positive coverage policies for the Afirma Gene Expression Classifier (GEC), deeming it a medically necessary benefit for their nearly 24 million collective members. The genomic test, which is used in thyroid cancer diagnosis, is now covered...